Dendritic cell vaccine - Bioclones/Hemispherx Biopharma

Drug Profile

Dendritic cell vaccine - Bioclones/Hemispherx Biopharma

Alternative Names: Cancer vaccine - Bioclones; Patient-specific DC immunotherapy vaccine - Bioclones/Hemispherx Biopharma

Latest Information Update: 18 Jul 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bioclones
  • Developer Bioclones; Hemispherx Biopharma
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Cancer
  • Preclinical Breast cancer; Prostate cancer

Most Recent Events

  • 14 Jul 2014 Bioclones and Hemispherx agree to collaborate in development of an adjuvanted form of the dendritic cell vaccine
  • 14 Jul 2014 Preclinical trials in Breast cancer in South Africa (Parenteral)
  • 14 Jul 2014 Preclinical trials in Prostate cancer in South Africa (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top